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Th   e study by Wattmo and colleagues published recently 
in Alzheimer’s Research & Th  erapy is a welcome addition 
to the literature on predictors of cognitive decline in 
Alzheimer’s disease (AD) [1]. A large number of risk 
factors for cognitive decline and AD in the population 
have been identiﬁ   ed and studied in detail [2-6]. In 
contrast, relatively little is known about factors that aﬀ  ect 
progression of cognitive and functional decline once the 
diagnosis of dementia is established. Th   e median survival 
time after onset of AD symptoms can be as high as 
11 years [7,8], and it is important for both clinical manage-
ment and caregiver counseling to be able to predict the 
probable time course of an individual’s loss of cognitive 
and functional abilities. A critical question for clinicians 
is whether long-term treatment with anti-dementia 
drugs, beyond the intervals documented in clinical trials, 
is beneﬁ  cial in altering progression rates. Clinical trials 
cannot supply this information because of their relatively 
brief duration compared with the number of years that 
people actually live with the disease. Naturalistic studies, 
on the other hand, are limited because they are not 
randomized with respect to drug use and often suﬀ  er 
from attrition and other biases.
Th   e meticulous study by Wattmo and colleagues is an 
important contribution to our understanding of factors 
that aﬀ   ect the cognitive response (Mini-Mental Status 
Exami na tion and Alzheimer’s Assessment Scale – 
cognitive subscale) to initiation and maintenance of 
cholinesterase inhibitor (ChEI) treatment over 3 years in 
a large cohort of patients with possible or probable AD 
[1]. Th  e main objective of the study was to compare 
outcomes for the three diﬀ   erent ChEIs (donepezil, 
rivastigmine, and galan  tamine). In contrast to other 
observational studies in which an untreated reference 
group was identiﬁ  ed [9,10], this study does not address the 
issue of whether treat  ment was helpful compared with no 
treatment. Outcomes in Wattmo and colleagues’ study 
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© 2011 BioMed Central Ltdwere not dependent upon the particular ChEI. Th  e  most 
interesting ﬁ   ndings in this report thus involve 
interactions between certain back  ground variables (age, 
gender, education level, and baseline cognitive scores) 
and the longitudinal outcomes studied. In particular, 
older men (age 85) with worse baseline Alzheimer’s 
Assessment Scale – cognitive sub  scale performance 
showed the greatest improvement in cognitive scores 
after treatment initiation. Although higher education was 
associated with better baseline cognitive scores, indi-
viduals with higher educational attain  ment experienced 
an accelerated rate of cognitive decline over time. Th  e 
general ﬁ  nding that older individuals and more severe 
patients had more improve  ment after initiation of 
treatment is important, since clinicians and family 
members may be tempted to view treatment as more 
futile or less beneﬁ  cial in these subsets of patients.
Another clinically signiﬁ  cant result reported by Wattmo 
and colleagues is the clear observation of an initial 
improvement in the responsive subgroups at 6 months, 
followed by nearly parallel trajectories of decline over the 
next 30 months. Although cognitive function continues 
to decline, initiation of ChEI treatment establishes a new, 
higher, baseline of performance for the individual. Th  is 
ﬁ  nding adds further evidence to support the persistent 
use of ChEI treatment over a long time period [10]. Th  e 
modeling results, and the graphic presentation of these 
results, also emphasize the point that baseline cognitive 
scores are highly predictive of cognitive outcomes 
observed over time. In Wattmo and colleagues’ popula-
tion, even though ChEI treatment initiation produced 
greater improvement in more severe patients, those 
improve  ments, in general, did not lead to better long-
term outcomes compared with patients who started out 
with milder dementia. Th  is  ﬁ  nding is consistent with the 
report by Doody and colleagues that a standardized 
clinician assessment of the annual rate of Mini-Mental 
Status Examination decline from onset of symptoms to 
diagnosis – the pre-progression rate – predicted the 
subse  quent trajectory of cognitive and functional out-
comes over as many as 7 years of follow-up [11].
In many societies, educational attainment is strongly 
correlated with pre-morbid IQ. Th  e construct of cogni-
tive reserve has been elaborated to explain the phenome-
non that individuals with high pre-morbid cognitive 
functioning perform better on cognitive tests after an AD 
diagnosis than those with lower pre-morbid functioning. 
Some studies, including that of Wattmo and colleagues, 
ﬁ   nd that persons with higher educational attainment 
decline faster after diagnosis than those with lower 
education [1,12,13]. In our own analysis of progression 
rates, however, higher education was associated with 
slower decline [14], a result also seen in some other 
analyses. Furthermore, we found that education was not 
even a signiﬁ  cant predictor of out  comes after accounting 
for pre-morbid IQ, suggesting that IQ may be a better 
surrogate for cognitive reserve. Data from the Scottish 
birth cohort studies indicate that higher IQ measured in 
childhood, before the individual’s ultimate educational 
status is known, reduces the risk of late-onset dementia 
[15]. In their discussion, Wattmo and colleagues suggest 
that the discrepant results for education between their 
cohort and ours may be attribu  table to diﬀ  erences in the 
mean educational level of the participants. Mean educa-
tion across clinical cohorts varies, as does the relationship 
among  educa tional  attain ment,  socio economic  status, 
and general cognitive ability. Th  is variability argues for 
the use of pre-morbid IQ instead of education as the 
predictor of interest. To advance our understanding of 
how pre-morbid cognitive ability aﬀ  ects the course of 
cognitive decline in AD, it would be highly desirable for 
AD research groups and clinical centers to include a 
measure of pre-morbid IQ, either with or without 
education, in their models of progression. Th  is practice 
would greatly accelerate the development of a consensus 
regarding the role of cogni  tive reserve in both response 
to treatment and the overall rate of decline after 
diagnosis.
In conclusion, rigorous observational studies – with 
careful documentation of both the drug exposure of 
interest and the outcomes following exposure – are a 
necessary supplement to data generated in clinical trials. 
We would argue that studies such as this one authored by 
Wattmo and colleagues are necessary to make informed 
treatment recommendations for practice guidelines, and 
to provide accurate prognostic information to patients 
and their families. We hope Wattmo and colleagues’ 
study will serve as a model for quality naturalistic AD 
research, with the caveat that pre-morbid IQ should be 
included whenever possible as a potential explanatory 
variable.
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